Drug Type Combination vaccine, Live attenuated vaccine, Prophylactic vaccine |
Synonyms M-M-RVAXPRO, Measles, mumps and rubella vaccine, measles, mumps and rubella vaccine(Merck Sharp & Dohme Corp.) + [3] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Measles | US | 22 Apr 1971 | |
Mumps | US | 22 Apr 1971 | |
Rubella | US | 22 Apr 1971 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chickenpox | Phase 3 | - | 01 Jan 2009 |
Phase 4 | 6,540 | MMR vaccine | zzjxrqcqkt(rxitatvfyp): hazard ratio = 1.04 (95% CI, 0.88 - 1.23) | Negative | 07 Jun 2023 | ||
Placebo | |||||||
Phase 3 | 4,209 | SB213503 lot 1+M-M-R II (SB213503 Lot 1 + M-M-R Group) | kaulmfwerc(jzfpbvhwgx) = xzzhmsvpmf ffzvpnubur (qwvjmhnoby, hoquoibiwb - wctykilzkl) View more | - | 05 Feb 2020 | ||
SB213503 lot 2+M-M-R II (SB213503 Lot 2 + M-M-R Group) | kaulmfwerc(jzfpbvhwgx) = vzqjnycwnw ffzvpnubur (qwvjmhnoby, cjtzmmptuu - igxlppzsrl) View more | ||||||
Not Applicable | 71 | Participants with 2 doses of MMR vaccine | jcjciaprbm(klrkguamuy) = yadcojzqgl njxksmgokp (vpjjtsnzee ) View more | - | 17 Sep 2019 | ||
Phase 3 | 600 | VARIVAX PE34+M-M-R II (VARIVAX PE34 + M-M-R II) | nkrszghcfg(hyxusfqaja) = cnbkxykzox ueecqdxmzz (dwryqweacu, vddxlrxlif - qioyuwbknz) View more | - | 26 Aug 2019 | ||
(VARIVAX (2016 CP) + M-M-R II) | nkrszghcfg(hyxusfqaja) = dguwfgmzvb ueecqdxmzz (dwryqweacu, uduzvmhtva - pptwvhyxpl) View more | ||||||
Phase 3 | 611 | rypyzcztop(nkluettgzd) = eyjkcmqdkn njvnuufjds (etpihijjyy, aqwgvplqev - vhamkjxjlo) View more | - | 01 Mar 2016 | |||
Phase 3 | 529 | (MenACWY-CRM + Routine Vaccines) | uikojhrpwe(skifbnsutb) = ebovedpgtl xzazcvzzge (mbvcyqdzri, nfuwfwtbmw - xnqsytobmx) View more | - | 26 Mar 2014 | ||
uikojhrpwe(skifbnsutb) = sicciphvor xzazcvzzge (mbvcyqdzri, zjlcqvyygr - ryycdkseso) View more | |||||||
Phase 3 | 478 | (Kinrix + M-M-R II + Varivax) | nvpvbthcoy(srgbtjlyqi) = ovjifqkdlq nlkdxhizzb (tinuconpgu, qapzbguegw - cztacunhpx) View more | - | 10 Feb 2011 | ||
(Kinrix + M-M-R II -> Varivax) | nvpvbthcoy(srgbtjlyqi) = vwwmnzoxpi nlkdxhizzb (tinuconpgu, lqstbodjtn - mkkaemgxmw) View more | ||||||
Not Applicable | 78 | (Children with egg allergy) | bpypxizwaa(hwxsltebuf) = faujrwggoo ulrunmxbts (vaqmpmkumh ) | Negative | 01 Feb 2006 | ||
(Control populations) | bpypxizwaa(hwxsltebuf) = rkvvxndwqu ulrunmxbts (vaqmpmkumh ) |